---
title: UK pharma media reputation tracker – H1 2026
canonical_url: https://www.omniscan.ai/benchmarks/uk-pharma-2026-h1
type: dataset
publisher: Omniscan
sector: Pharma in the UK
period: H1 2026
coverage_start: '2026-01-01'
coverage_end: '2026-06-30'
date_published: '2026-09-01'
last_updated: '2026-09-01'
organisations: 10
articles_analysed: 4511
mentions: 3556
data_download: https://www.omniscan.ai/benchmarks/uk-pharma-2026-h1/data.json
summary: Eli Lilly had the highest average monthly share of coverage (23.7%) among
  10 companies in UK earned media from 1 January 2026 to 30 June 2026, ahead of Novo
  Nordisk (20.8%) and GSK (18.4%).
---

# UK pharma media reputation tracker: H1 2026 (1 January 2026–30 June 2026)

> Eli Lilly had the highest average monthly share of coverage (23.7%) among 10 companies in UK earned media from 1 January 2026 to 30 June 2026, ahead of Novo Nordisk (20.8%) and GSK (18.4%). Moderna had the most favourable net tone (+63). Omniscan analysed 4,511 articles containing 3,556 mentions of the companies tracked.

Interactive version: https://www.omniscan.ai/benchmarks/uk-pharma-2026-h1

## Pharma in the UK ranking by share of coverage, H1 2026

| Rank | Organisation | Average monthly share of coverage | Mentions | Positive | Neutral | Negative | Net tone |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1 | Eli Lilly | 23.7% | 848 | 27% | 58% | 15% | +12 |
| 2 | Novo Nordisk | 20.8% | 747 | 31% | 52% | 17% | +15 |
| 3 | GSK | 18.4% | 649 | 64% | 32% | 4% | +59 |
| 4 | AstraZeneca | 18.2% | 652 | 67% | 25% | 8% | +59 |
| 5 | Pfizer | 4.7% | 174 | 26% | 49% | 25% | +1 |
| 6 | MSD | 3.4% | 110 | 43% | 33% | 24% | +20 |
| 7 | Roche | 2.9% | 101 | 34% | 46% | 20% | +14 |
| 7 | Sanofi | 2.9% | 106 | 34% | 34% | 32% | +2 |
| 9 | Novartis | 2.5% | 89 | 31% | 61% | 8% | +24 |
| 10 | Moderna | 2.3% | 80 | 66% | 30% | 4% | +63 |

## Monthly share of coverage, Pharma in the UK

| Organisation | January 2026 | February 2026 | March 2026 | April 2026 | May 2026 | June 2026 |
| --- | --- | --- | --- | --- | --- | --- |
| Eli Lilly | 26.2% | 28.0% | 29.6% | 18.9% | 22.8% | 17.1% |
| Novo Nordisk | 22.3% | 20.0% | 20.0% | 19.7% | 18.6% | 23.9% |
| GSK | 13.6% | 20.0% | 17.6% | 15.2% | 17.2% | 27.1% |
| AstraZeneca | 18.6% | 20.0% | 13.7% | 24.1% | 19.5% | 13.5% |
| Pfizer | 6.0% | 3.4% | 5.0% | 5.4% | 3.0% | 5.5% |
| MSD | 2.6% | 2.5% | 1.7% | 3.5% | 7.7% | 2.7% |
| Roche | 3.0% | 0.5% | 5.3% | 3.3% | 3.3% | 2.3% |
| Sanofi | 3.1% | 2.3% | 3.8% | 3.2% | 1.8% | 3.3% |
| Novartis | 3.2% | 1.5% | 2.9% | 2.5% | 3.0% | 2.0% |
| Moderna | 1.4% | 2.0% | 0.4% | 4.3% | 3.3% | 2.7% |

## Companies in detail

### Eli Lilly

**Lilly rebounded to second place as Foundayo launched in the UK**

Eli Lilly ranked 1st of 10 by average monthly share of coverage (23.7%) in the Pharma in the UK benchmark for H1 2026, with 848 mentions and a net tone of +12.

Lilly ranked first from January through March as its share rose from 26.2% to 29.6%, even as monthly volume declined. March broadened the profile through the proposed Centessa acquisition, negotiations over NHS medicine pricing and a successful appeal requiring NICE to reconsider donanemab guidance. January 2026: BBC reported the theft of temperature-sensitive Mounjaro from a St Albans pharmaceutical distributor. February 2026: share rose 1.8 points to 28.0% while volume fell by 30; stories included orforglipron’s phase-three comparison with oral semaglutide and uneven NHS access to Mounjaro. April 2026: share fell 10.7 points to 18.9% and Lilly moved from first to third; stories included Mounjaro’s UK paediatric approval and draft NICE support for Jaypirca. February 2026: The Pharmaceutical Journal reported phase-three results comparing orforglipron with oral semaglutide. March 2026: The Wall Street Journal reported Lilly’s agreement to acquire Centessa Pharmaceuticals for $6.3 billion upfront. April 2026: The Pharmaceutical Journal reported Mounjaro’s UK approval for children aged ten and over with insufficiently controlled type 2 diabetes. June 2026: Pharmaphorum reported the UK launch of LillyDirect as a post-prescription dispensing and delivery service. Eli Lilly forecast strong sales growth for Mounjaro and Zepbound while Novo Nordisk warned of falling sales amid obesity-drug competition. GSK said it would focus on diseases associated with obesity rather than develop weight-loss medicines.

Key messages:

- January 2026: BBC reported the theft of temperature-sensitive Mounjaro from a St Albans pharmaceutical distributor.
- Eli Lilly forecast strong sales growth for Mounjaro and Zepbound while Novo Nordisk warned of falling sales amid obesity-drug competition. GSK said it would focus on diseases associated with obesity rather than develop weight-loss medicines.
- A Nottinghamshire woman says weight loss while taking Mounjaro helped her discover a breast lump and receive a cancer diagnosis. The article also notes common and rare reported side effects of the medicine.
- UK GPs will receive incentives to prescribe Eli Lilly's Mounjaro and refer eligible patients to weight-management services. The NHS is widening phased access while addressing uneven prescribing and unsafe private supply.
- NICE must reconsider its guidance excluding Eli Lilly's Alzheimer’s drug donanemab from NHS use after Lilly's successful appeal. The review concerns cost-effectiveness assumptions, including carer costs and infusion estimates.
- Eli Lilly agreed to buy UK-based clinical-stage company Centessa Pharmaceuticals for $6.3 billion upfront, potentially rising to $7.8 billion. The acquisition expands Lilly into sleep medicine and neuroscience.

Leading themes:

- Medicines Safety, Supply & Patient Use: 57.8% of Eli Lilly's coverage (theme index 3.57, net tone +3)
- NHS Access & Pricing: 17.6% of Eli Lilly's coverage (theme index 1.54, net tone +8)
- Clinical Trials & Research: 5.7% of Eli Lilly's coverage (theme index 0.47, net tone +29)

Notable positive coverage:

- 4 February 2026, thisismoney.co.uk: [Mounjaro maker Eli Lilly flattens Wegovy rival Novo Nordisk in battle of the fat jabs](https://www.thisismoney.co.uk/money/markets/article-15528405/Mounjaro-maker-Eli-Lilly-flattens-Wegovy-rival-Novo-Nordisk-battle-fat-jabs.html). Eli Lilly forecast strong sales growth for Mounjaro and Zepbound while Novo Nordisk warned of falling sales amid obesity-drug competition. GSK said it would focus on diseases associated with obesity rather than develop weight-loss medicines.
- 9 February 2026, bbc.com: [Weight-loss jab Mounjaro helped Nottinghamshire woman find cancer](https://www.bbc.com/news/articles/cn0yl9v0x4go). A Nottinghamshire woman says weight loss while taking Mounjaro helped her discover a breast lump and receive a cancer diagnosis. The article also notes common and rare reported side effects of the medicine.
- 24 February 2026, pharmaphorum.com: [UK spurs prescribing of obesity jab Mounjaro with GP bonus](https://pharmaphorum.com/news/uk-spurs-prescribing-obesity-jab-mounjaro-gp-bonus). UK GPs will receive incentives to prescribe Eli Lilly's Mounjaro and refer eligible patients to weight-management services. The NHS is widening phased access while addressing uneven prescribing and unsafe private supply.

Notable negative coverage:

- 8 June 2026, inews.co.uk: [I lost three stone on Mounjaro but ended up in hospital - what they found shocked me](https://inews.co.uk/inews-lifestyle/weight-loss-mounjaro-hospital-shocked-4459508). A UK patient describes gallstones and prolonged NHS surgical waits after losing weight on Mounjaro. The article notes that rapid weight loss and GLP-1 medicines can be associated with gallbladder events.
- 29 May 2026, theguardian.com: [Huge haul of weight-loss drugs seized in Northampton country estate](https://www.theguardian.com/uk-news/2026/may/29/huge-haul-weight-loss-drugs-seized-northampton-country-estate). The MHRA seized about 12,000 doses of unlicensed weight-loss medicines, including illicit tirzepatide products, from a Northamptonshire estate. Two men were arrested in the operation targeting unsafe counterfeit and unlicensed supply.
- 24 April 2026, mirror.co.uk: [Dad who thought he had trapped wind almost died after fat jab mistake](https://www.mirror.co.uk/news/health/dad-who-thought-trapped-wind-37063981). A man from Oldham required emergency surgery for gangrenous cholecystitis after rapid weight loss while using Mounjaro bought online. Eli Lilly said the risk is listed in the medicine information and that it reports safety information to the MHRA.

- [Eli Lilly deep dive](https://www.omniscan.ai/benchmarks/uk-pharma-2026-h1?entity=elililly&view=deep-dive)
- [Eli Lilly PDF report](https://www.omniscan.ai/benchmarks/uk-pharma-2026-h1/reports/elililly.pdf)

### Novo Nordisk

**Novo Nordisk’s Wegovy expansion meets a broader pipeline test**

Novo Nordisk ranked 2nd of 10 by average monthly share of coverage (20.8%) in the Pharma in the UK benchmark for H1 2026, with 747 mentions and a net tone of +15.

It opened at 22.3% and second place in January, then occupied second place through April before moving between second and third over the remaining months. Safety remained the leading subject in February and March, with reporting focusing particularly on rare sight-loss warnings and studies, while CagriSema’s trial result and lower-cost Indian semaglutide products added competitive and patent pressure. April broadened the agenda as NICE recommended Wegovy for cardiovascular-risk reduction among eligible NHS patients and delivery requirements were eased. May’s 18.6% share and third-place position coincided with STEP UP and oral-semaglutide trial analyses, alongside Novo Nordisk’s court action against counterfeit Ozempic websites. Novo Nordisk’s share rose to the period’s highest level, 23.9%, in June. January 2026: The Guardian reported Novo Nordisk’s US launch of the Wegovy pill and the UK regulatory review. February 2026: share fell 2.3 points to 20% and volume fell by 51, while Novo Nordisk remained second; stories included the MHRA’s rare sight-loss warning for Ozempic and Wegovy. February 2026: The Times reported the MHRA warning concerning a very rare risk of sudden sight loss associated with semaglutide medicines. June 2026: BBC News reported the UK approval of oral Wegovy, with NHS availability still subject to further assessment.

Key messages:

- January 2026: The Guardian reported Novo Nordisk’s US launch of the Wegovy pill and the UK regulatory review.
- The MHRA has approved Novo Nordisk's 7.2mg Wegovy dose for UK use, supported by trial results showing substantial weight loss. The article also reports evidence on GLP-1 medicine use, side effects and weight regain after treatment stops.
- The article assesses Novo Nordisk's oral Wegovy in the UK, including private pricing, limited NHS availability, effectiveness and side effects. It compares Wegovy with Eli Lilly's Mounjaro and raises concerns about muscle loss and weight regain after stopping treatment.
- The MHRA issued a new warning that semaglutide may very rarely be associated with NAION, a condition affecting the optic nerve. Semaglutide is marketed as Ozempic, Rybelsus, and Wegovy.
- A UK colorectal surgeon warns about gastrointestinal effects and inappropriate lifestyle use of GLP-1 weight-loss medicines including Ozempic and Wegovy. The article highlights constipation and uncertainty about long-term consequences for some users.
- A review of studies found that a substantial share of weight lost on GLP-1 injections was fat-free mass, including muscle and bone, raising concerns about frailty and fracture risk. The article references semaglutide brands Ozempic and Wegovy.

Leading themes:

- Medicines Safety, Supply & Patient Use: 50.2% of Novo Nordisk's coverage (theme index 2.55, net tone −20)
- Drug Approvals & Launches: 14.3% of Novo Nordisk's coverage (theme index 5.83, net tone +78)
- NHS Access & Pricing: 13.7% of Novo Nordisk's coverage (theme index 1.08, net tone +47)

Notable positive coverage:

- 6 January 2026, dailymail.com: [Don't like fat jabs? Soon weight-loss drug Wegovy could be taken as a pill in UK after being launched in US](https://www.dailymail.com/news/article-15437117/fat-jabs-weight-loss-drug-Wegovy-pill-UK.html). Novo Nordisk launched an oral Wegovy treatment in the US and expects a UK MHRA decision on its application by the end of 2026. The article says Eli Lilly expects a comparable US regulatory decision in March.
- 12 January 2026, inews.co.uk: [What is 'natural Ozempic' - and how good is the science?](https://inews.co.uk/news/natural-ozempic-works-good-science-4156305). The article examines evidence behind a supplement marketed as "natural Ozempic" and contrasts it with GLP-1 medicines. It reports MHRA approval of Novo Nordisk's higher-dose Wegovy in the UK and discusses Mounjaro as a rival treatment.
- 12 January 2026, independent.co.uk: [Wegovy to launch stronger dose weight-loss jabs as UK usage set to soar](https://www.independent.co.uk/news/health/weight-loss-jab-wegovy-mounjaro-regulator-mhra-b2897695.html). The MHRA has approved Novo Nordisk's 7.2mg Wegovy dose for UK use, supported by trial results showing substantial weight loss. The article also reports evidence on GLP-1 medicine use, side effects and weight regain after treatment stops.

Notable negative coverage:

- 7 January 2026, independent.co.uk: [People on fat loss jabs 'put weight back on faster than traditional dieters'](https://www.independent.co.uk/news/health/people-nhs-wegovy-mounjaro-university-of-oxford-b2896492.html). Oxford researchers found rapid weight regain and loss of health benefits after stopping Wegovy or Mounjaro. The article discusses NHS treatment limits, private purchasing and potential nutritional risks.
- 6 February 2026, bmj.com: [GLP-1 drugs: New eyesight warning for Ozempic/Wegovy](https://www.bmj.com/content/392/bmj.s252.short). The MHRA issued a new warning that semaglutide may very rarely be associated with NAION, a condition affecting the optic nerve. Semaglutide is marketed as Ozempic, Rybelsus, and Wegovy.
- 17 June 2026, telegraph.co.uk: [Six surprising habits wrecking your gut health](https://www.telegraph.co.uk/health-fitness/diet/gut-health/six-surprising-habits-wrecking-your-gut-health/). A UK colorectal surgeon warns about gastrointestinal effects and inappropriate lifestyle use of GLP-1 weight-loss medicines including Ozempic and Wegovy. The article highlights constipation and uncertainty about long-term consequences for some users.

- [Novo Nordisk deep dive](https://www.omniscan.ai/benchmarks/uk-pharma-2026-h1?entity=novonordisk&view=deep-dive)
- [Novo Nordisk PDF report](https://www.omniscan.ai/benchmarks/uk-pharma-2026-h1/reports/novonordisk.pdf)

### GSK

**M&A & Licensing shaped GSK's media profile during H1 2026**

GSK ranked 3rd of 10 by average monthly share of coverage (18.4%) in the Pharma in the UK benchmark for H1 2026, with 649 mentions and a net tone of +59.

GSK began fourth in January at 13.6%, amid extensive independent reporting of its $2.2bn RAPT Therapeutics acquisition and positive bepirovirsen studies. February’s share rose 6.4 points to 20.0% and second place, alongside results coverage, R&D job cuts and the $950m purchase of 35Pharma. It moved back to third in March and fourth in April as the agenda shifted through the linerixibat licensing agreement, meningitis vaccines, first-quarter results and early Mo-Rez cancer data. May’s share was 17.2% in fourth place, with fewer GSK mentions and reporting on bepirovirsen’s Phase III results, its prospective Chinese launch and a SiranBio licensing deal. June brought GSK’s strongest competitive position at 27.1% and first place; stories included the $10.6bn Nuvalent takeover. February 2026: GSK agreed to buy 35Pharma for $950m and add a pulmonary-hypertension candidate, reported by Reuters. March 2026: GSK transferred worldwide linerixibat development and commercialisation rights to Alfasigma, reported by Reuters. April 2026: early Mo-Rez data supported plans for five Phase III cancer trials, reported by the Financial Times. June 2026: GSK agreed the $10.6bn takeover of lung-cancer drug developer Nuvalent, reported by Reuters. GSK said its late-stage bepirovirsen trials showed a statistically significant and clinically meaningful functional cure rate for chronic hepatitis B. The result could support regulatory submissions and strengthen its pipeline.

Key messages:

- January 2026: GSK agreed its $2.2bn acquisition of food-allergy drug developer RAPT Therapeutics, reported by The Guardian.
- GSK said its late-stage bepirovirsen trials showed a statistically significant and clinically meaningful functional cure rate for chronic hepatitis B. The result could support regulatory submissions and strengthen its pipeline.
- GSK said its experimental chronic hepatitis B treatment bepirovirsen met the main goal in two studies. The positive data could support future approval and contribute to GSK's growth targets.
- GSK reported positive trial results for bepirovirsen in chronic hepatitis B, with significantly higher functional cure rates than standard care alone. The article also considers the potential commercial contribution of the medicine to GSK's 2031 targets.
- GSK reported positive phase 3 results for bepirovirsen in chronic hepatitis B and plans global regulatory filings within three months. The company forecasts potential peak sales of around £2 billion if the drug reaches market.
- The MHRA approved GSK's Nucala for adults with uncontrolled eosinophilic COPD in the UK. NICE is expected to decide later this year whether to recommend it for NHS use.

Leading themes:

- M&A & Licensing: 39.6% of GSK's coverage (theme index 4.41, net tone +73)
- Financial Results & Pipeline: 21.6% of GSK's coverage (theme index 2.27, net tone +49)
- Leadership & Strategy: 9.7% of GSK's coverage (theme index 2.03, net tone +38)

Notable positive coverage:

- 7 January 2026, ft.com: [GSK hails promising trial results for hepatitis B treatment](https://www.ft.com/content/a51aaf32-0122-4397-8a8a-d10cf0da74f5?syn-25a6b1a6=1). GSK said its late-stage bepirovirsen trials showed a statistically significant and clinically meaningful functional cure rate for chronic hepatitis B. The result could support regulatory submissions and strengthen its pipeline.
- 7 January 2026, reuters.com: [GSK's chronic hepatitis B treatment meets main goal in key studies](https://www.reuters.com/business/healthcare-pharmaceuticals/gsks-chronic-hepatitis-b-treatment-meets-main-goal-key-studies-2026-01-07/). GSK said its experimental chronic hepatitis B treatment bepirovirsen met the main goal in two studies. The positive data could support future approval and contribute to GSK's growth targets.
- 7 January 2026, thetimes.com: [GSK's hepatitis B drug shows promise in trials](https://www.thetimes.com/business/companies-markets/article/gsks-hepatitis-b-drug-shows-promise-in-trials-whct83pkm). GSK reported positive trial results for bepirovirsen in chronic hepatitis B, with significantly higher functional cure rates than standard care alone. The article also considers the potential commercial contribution of the medicine to GSK's 2031 targets.

Notable negative coverage:

- 2 February 2026, standard.co.uk: [GSK cutting jobs in UK and US as part of ongoing R&D changes](https://www.standard.co.uk/news/science/gsk-stevenage-hertfordshire-b1269288.html). GSK is cutting up to 350 R&D jobs across the UK and US, with around 50 roles affected at Stevenage. It says UK R&D investment and investment in key research sites will continue.
- 30 April 2026, finance.yahoo.com: [JP Morgan retains 'underweight' on GSK with £17 price target as earnings upgrade potential seen as limited](https://finance.yahoo.com/sectors/healthcare/articles/jp-morgan-retains-underweight-gsk-133200075.html). JP Morgan retained an underweight rating on GSK, citing limited potential for earnings upgrades and execution risks around pipeline launches. The broker highlighted upcoming clinical-trial readouts and GSK's next results update.
- 2 February 2026, sharecast.com: [GSK to cut up to 350 R&D jobs across UK, US](https://www.sharecast.com/news/news-and-announcements/gsk-to-cut-up-to-350-rd-jobs-across-uk-us--21593569.html). GSK plans to cut up to 350 R&D jobs across the UK and US, including around 50 roles at its Stevenage R&D hub. The company says R&D spending will continue to rise.

- [GSK deep dive](https://www.omniscan.ai/benchmarks/uk-pharma-2026-h1?entity=gsk&view=deep-dive)
- [GSK PDF report](https://www.omniscan.ai/benchmarks/uk-pharma-2026-h1/reports/gsk.pdf)

### AstraZeneca

**Financial Results & Pipeline shaped AstraZeneca's media profile during H1 2026**

AstraZeneca ranked 4th of 10 by average monthly share of coverage (18.2%) in the Pharma in the UK benchmark for H1 2026, with 652 mentions and a net tone of +59.

The company moved from third place at 18.6% in January to second at 20.0% in February, before falling to fourth at 13.7% in March. January coverage centred on the CSPC obesity collaboration, the Modella AI acquisition and China investment, while February shifted towards annual results and cancer-drug demand. March’s smaller share coincided with trial reporting on tozorakimab and mixed efzimfotase alfa results. AstraZeneca returned to first place at 24.1% in April, when stories included first-quarter growth and a renewed £300 million investment in Cambridge and Macclesfield. It was second at 19.5% in May and fourth at 13.5% in June, as coverage included camizestrant’s contrasting US and EU regulatory outcomes, expanded oncology collaborations and phase-two elecoglipron data. January 2026: AstraZeneca’s CSPC collaboration added weight-management and diabetes programmes to its pipeline, reported by The Independent. February 2026: share rose 1.4 percentage points to 20.0% and rank improved from third to second; stories included annual profit growth and continued cancer-drug demand. February 2026: AstraZeneca forecast further growth after higher sales and profit, with oncology central to the results, reported by Reuters. March 2026: tozorakimab reduced COPD flare-ups in two late-stage trials, reported by Reuters.

Key messages:

- January 2026: AstraZeneca’s CSPC collaboration added weight-management and diabetes programmes to its pipeline, reported by The Independent.
- AstraZeneca appointed Rick Suarez as president of its US BioPharmaceuticals Business Unit. He will lead major US manufacturing and R&D investment as the company pursues its 2030 revenue target.
- AstraZeneca agreed to acquire Modella AI to integrate AI into oncology clinical development and accelerate drug discovery. The article also outlines AstraZeneca's pipeline, revenue ambitions and patent-loss mitigation strategy.
- AstraZeneca has applied to build a six-storey office and conference facility at the Cambridge Biomedical Campus, accommodating up to 736 staff. Cambridge City Council will consider the planning application.
- AstraZeneca paid $630 million to obtain full China rights to AbelZeta's anti-GPC3 CAR-T therapy C-CAR031, also known as AZD7003. The agreement expands AstraZeneca's oncology cell-therapy strategy.
- AstraZeneca faces criticism for encouraging online participation at its London AGM, with campaigners saying the approach limits shareholder scrutiny. The company says shareholders can participate and ask questions digitally.

Leading themes:

- Financial Results & Pipeline: 25.6% of AstraZeneca's coverage (theme index 2.99, net tone +68)
- Clinical Trials & Research: 15.6% of AstraZeneca's coverage (theme index 1.68, net tone +76)
- UK Investment & Manufacturing: 14.6% of AstraZeneca's coverage (theme index 6.72, net tone +61)

Notable positive coverage:

- 8 January 2026, reuters.com: [AstraZeneca names insider Rick Suarez head of US biopharmaceuticals unit](https://www.reuters.com/business/healthcare-pharmaceuticals/astrazeneca-names-rick-suarez-head-us-biopharmaceuticals-unit-2026-01-08/). AstraZeneca appointed Rick Suarez to lead its US biopharmaceuticals unit. He will oversee the company’s previously announced $50bn US research, development and manufacturing investment.
- 9 January 2026, europeanpharmaceuticalreview.com: [AstraZeneca hires Rick Suarez to lead its biopharma efforts in the US](https://www.europeanpharmaceuticalreview.com/news/astrazeneca-hires-rick-suarez-to-lead-its-biopharma-efforts-in-the-us/270051.article). AstraZeneca appointed Rick Suarez as president of its US BioPharmaceuticals Business Unit. He will lead major US manufacturing and R&D investment as the company pursues its 2030 revenue target.
- 13 January 2026, finance.yahoo.com: [AstraZeneca to acquire Modella AI to speed oncology drug research](https://finance.yahoo.com/news/astrazeneca-acquire-modella-ai-speed-170943466.html). AstraZeneca has agreed to acquire Boston-based Modella AI to add AI capabilities to oncology research, clinical development and biomarker discovery. The deal supports AstraZeneca's broader growth and pipeline strategy.

Notable negative coverage:

- 4 April 2026, thisismoney.co.uk: [AstraZeneca accused of dodging its investors by making AGM online only](https://www.thisismoney.co.uk/money/markets/article-15706255/AstraZeneca-accused-dodging-investors-making-AGM-online-only.html). AstraZeneca faces criticism for encouraging online participation at its London AGM, with campaigners saying the approach limits shareholder scrutiny. The company says shareholders can participate and ask questions digitally.
- 16 June 2026, telegraph.co.uk: [Covid jab victim killed himself after being denied compensation](https://www.telegraph.co.uk/news/2026/06/16/covid-jab-victim-killed-himself-after-denied-compensation/). The family of a man paralysed after receiving AstraZeneca's Covid vaccine received compensation through the UK's Vaccine Damage Payment Scheme after a lengthy appeal. The article highlights calls to reform the UK compensation system for rare vaccine injuries.
- 13 June 2026, mirror.co.uk: [Dying mum begs to see daughter's prom as she's denied any extra time with family](https://www.mirror.co.uk/news/uk-news/dying-mum-begs-see-daughters-37269723). Campaigners are urging AstraZeneca, Daiichi Sankyo, NICE and NHS England to agree an NHS access deal for Enhertu for HER2-low metastatic breast cancer. NICE says renewed commercial discussions are under way following changes to its cost-effectiveness threshold.

- [AstraZeneca deep dive](https://www.omniscan.ai/benchmarks/uk-pharma-2026-h1?entity=astrazeneca&view=deep-dive)
- [AstraZeneca PDF report](https://www.omniscan.ai/benchmarks/uk-pharma-2026-h1/reports/astrazeneca.pdf)

### Pfizer

**Pfizer’s visibility swung as safety coverage persisted**

Pfizer ranked 5th of 10 by average monthly share of coverage (4.7%) in the Pharma in the UK benchmark for H1 2026, with 174 mentions and a net tone of +1.

From February onwards, independent reporting on alleged meningioma risks and legal claims involving Depo-Provera became the most persistent strand across the window. April broadened the agenda through expanded NHS eligibility for Abrysvo, evidence on maternal RSV vaccination and a personalised patient-information project. The Innovent oncology collaboration emerged in May and continued into June, when Pfizer’s share recovered to 5.5% and fifth place. June also brought the Court of Appeal’s phenytoin pricing decision, a Pfizer complaint against Alnylam and separate BBC reports culminating in a coroner finding no evidence that a Covid-19 booster caused a woman’s death. January 2026: NICE recommended Talzenna with Xtandi for eligible metastatic prostate-cancer patients, reported by Pharmaceutical Technology. February 2026: share fell 2.6 percentage points to 3.4% while rank remained fifth; stories included The Guardian’s report on prospective Depo-Provera litigation and Reuters coverage of the PMCPA ruling following Pfizer’s complaint about Sanofi. February 2026: UK law firms considered claims concerning Depo-Provera and meningiomas, reported by The Guardian. May 2026: Pfizer agreed a 12-programme oncology collaboration with Innovent, reported by FirstWord Pharma. June 2026: the Court of Appeal reinstated the CMA’s phenytoin excessive-pricing finding, reported by Pharmacy Magazine. England will expand NHS eligibility for Pfizer's RSV vaccine Abrysvo to all adults aged 80 and over. The programme had selected Pfizer's vaccine ahead of rival products from GSK and AstraZeneca.

Key messages:

- January 2026: NICE recommended Talzenna with Xtandi for eligible metastatic prostate-cancer patients, reported by Pharmaceutical Technology.
- England will expand NHS eligibility for Pfizer's RSV vaccine Abrysvo to all adults aged 80 and over. The programme had selected Pfizer's vaccine ahead of rival products from GSK and AstraZeneca.
- Pfizer agreed a collaboration with Innovent Biologics covering 12 oncology programmes, with Innovent eligible for more than $10 billion in upfront and milestone payments. The companies plan to co-commercialise four programmes in the US, EU and UK.
- An inquest is investigating concerns that a Pfizer Covid-19 vaccine may have been linked to an 85-year-old woman’s fatal stroke. Her family believes the vaccination may have triggered her decline.
- A Scottish woman who says Depo-Provera caused tumours and partial blindness fears jurisdiction rules could prevent her joining a UK compensation claim against Pfizer. Pfizer said it continuously monitors medicine safety and maintains the contraceptive has an established safety profile.
- An inquest heard claims that an 85-year-old woman experienced symptoms before dying after receiving a Pfizer Covid booster. The article also recounts evidence concerning an earlier AstraZeneca vaccination, with no definitive causal finding reported.

Leading themes:

- M&A & Licensing: 21.3% of Pfizer's coverage (theme index 1.5, net tone +22)
- Medicines Safety, Supply & Patient Use: 18.4% of Pfizer's coverage (theme index 0.69, net tone −81)
- NHS Access & Pricing: 17.2% of Pfizer's coverage (theme index 1.36, net tone +10)

Notable positive coverage:

- 23 January 2026, firstwordpharma.com: [NICE U-turn allows NHS funding of Pfizer's Talzenna for prostate cancer](https://firstwordpharma.com/story/7078594). NICE has reversed its earlier position and recommended Pfizer's Talzenna with Xtandi for eligible adults with advanced prostate cancer in England. A confidential commercial arrangement will provide the medicine to the NHS at a discount.
- 26 January 2026, pharmaceutical-technology.com: [NICE greenlights Pfizer's Talzenna for NHS use](https://www.pharmaceutical-technology.com/news/uk-nice-recommends-pfizer-talzenna-metastatic-prostate-cancer/). NICE recommended Pfizer's Talzenna with Xtandi for eligible patients in England with metastatic prostate cancer. The decision reverses NICE's earlier provisional rejection and enables NHS access.
- 2 April 2026, bloomberg.com: [Pfizer's RSV Shot to Be Offered to 3 Million More in England](https://www.bloomberg.com/news/articles/2026-04-01/pfizer-s-rsv-shot-to-be-offered-to-3-million-more-in-england). England will expand NHS eligibility for Pfizer's RSV vaccine Abrysvo to all adults aged 80 and over. The programme had selected Pfizer's vaccine ahead of rival products from GSK and AstraZeneca.

Notable negative coverage:

- 22 June 2026, bbc.co.uk: [Mum's death after stroke investigated over Covid jab concerns](https://www.bbc.co.uk/news/articles/c3vy3nrlyrvo). An inquest is investigating concerns that a Pfizer Covid-19 vaccine may have been linked to an 85-year-old woman’s fatal stroke. Her family believes the vaccination may have triggered her decline.
- 11 February 2026, theguardian.com: [UK law firms consider action on behalf of women who developed brain tumours after using contraceptive](https://www.theguardian.com/business/2026/feb/11/uk-law-firms-consider-action-on-behalf-of-women-who-developed-brain-tumours-after-using-contraceptive). UK law firms are considering claims against Pfizer on behalf of women who developed meningiomas after using Depo-Provera. Pfizer is contesting litigation and says it continuously monitors medicine safety with health authorities.
- 22 June 2026, telegraph.co.uk: [Grandmother died a week after having Covid booster jab, inquest told](https://www.telegraph.co.uk/news/2026/06/22/mohinder-kaur-mahal-covid-booster-jab-derby/). An inquest heard claims that an 85-year-old woman experienced symptoms before dying after receiving a Pfizer Covid booster. The article also recounts evidence concerning an earlier AstraZeneca vaccination, with no definitive causal finding reported.

- [Pfizer deep dive](https://www.omniscan.ai/benchmarks/uk-pharma-2026-h1?entity=pfizer&view=deep-dive)
- [Pfizer PDF report](https://www.omniscan.ai/benchmarks/uk-pharma-2026-h1/reports/pfizer.pdf)

### MSD

**MSD coverage shifted from NHS access to clinical research**

MSD ranked 6th of 10 by average monthly share of coverage (3.4%) in the Pharma in the UK benchmark for H1 2026, with 110 mentions and a net tone of +20.

January’s company-focused evidence combined the Guardant Health oncology collaboration, the planned Cidara acquisition and a patient’s possible access to a pembrolizumab trial. One February UK court ruling in the Halozyme dispute, reported by two outlets, gave patents greater prominence before March centred on NICE’s recommendation of Keytruda for early head and neck cancer. April broadened the agenda through the NHS rollout of subcutaneous pembrolizumab and Enflonsia’s UK authorisation, alongside investigations into Keytruda pricing and patent practices and coverage of MSD’s withdrawal from Belgrove House. May produced the period’s highest share at 7.7%, with extensive reporting on the rapid Keytruda injection rollout in England and Wales and its availability at three Northern Ireland health trusts, plus a separate NICE recommendation for Winrevair. MSD’s share fell to 2.7% in June, when the subject mix was evenly divided between financial results and pipeline, NHS access and pricing, clinical research, and deals and licensing; stories included NICE’s recommendation of pembrolizumab for locally advanced cervical cancer. Visibility peaked in May 2026 at 7.7%, compared with 1.7% in March 2026. January 2026: Fierce Biotech reported MSD’s multiyear Guardant Health oncology collaboration covering clinical studies and companion diagnostics.

Key messages:

- Visibility peaked in May 2026 at 7.7%, compared with 1.7% in March 2026.
- January 2026: Fierce Biotech reported MSD’s multiyear Guardant Health oncology collaboration covering clinical studies and companion diagnostics.
- NICE has recommended MSD's Keytruda for perioperative treatment of eligible patients with resectable locally advanced head and neck cancer in England. The decision expands pembrolizumab's UK use to an earlier stage of care.
- The injectable form of MSD's Keytruda is rolling out in England and Wales, but is not yet available in Northern Ireland. Researchers warn this could create a postcode lottery, while Northern Ireland's Department of Health explores access options.
- The article describes how NHS use of injectable Keytruda could shorten cancer-treatment visits and free chemotherapy capacity. Keytruda is an MSD medicine.
- MSD withdrew from plans to occupy Belgrove House in King's Cross, citing UK competitiveness and medicines pricing. The developer is now seeking replacement occupiers for the London life-sciences building.

Leading themes:

- NHS Access & Pricing: 36.4% of MSD's coverage (theme index 3, net tone +40)
- M&A & Licensing: 17.3% of MSD's coverage (theme index 1.19, net tone +32)
- UK Investment & Manufacturing: 13.6% of MSD's coverage (theme index 3.29, net tone −73)

Notable positive coverage:

- 24 March 2026, pharmaphorum.com: [Keytruda cleared for NHS use in early head and neck cancer](https://pharmaphorum.com/news/keytruda-cleared-nhs-use-early-head-and-neck-cancer). NICE has recommended MSD's Keytruda for routine NHS England use before and after surgery in eligible early locally advanced head and neck cancer. The guidance starts a 90-day implementation period for NHS funding.
- 27 March 2026, manufacturingchemist.com: [NICE approves KEYTRUDA as first perioperative immunotherapy for locally advanced head and neck cancer](https://manufacturingchemist.com/nice-approves-msd-keytruda-perioperative-immunotherapy-head-cancer). NICE has recommended MSD's Keytruda for perioperative treatment of eligible patients with resectable locally advanced head and neck cancer in England. The decision expands pembrolizumab's UK use to an earlier stage of care.
- 5 May 2026, bbc.com: [Keytruda: New cancer jab available for patients at three health trusts](https://www.bbc.com/news/articles/cvgz91dkddno). Three Northern Ireland health trusts are using injectable Keytruda, following UK regulatory approval and rollout in England and Wales. The formulation is intended to reduce treatment time for cancer patients and NHS staff.

Notable negative coverage:

- 27 April 2026, building.co.uk: [Developer behind Mace’s King’s Cross life sciences building working with agents to find new occupiers after end-user pulled out last year](https://www.building.co.uk/news/developer-behind-maces-kings-cross-life-sciences-building-working-with-agents-to-find-new-occupiers-after-end-user-pulled-out-last-year/5141948.article). MSD withdrew from plans to occupy Belgrove House in King's Cross, citing UK competitiveness and medicines pricing. The developer is now seeking replacement occupiers for the London life-sciences building.
- 13 April 2026, thebureauinvestigates.com: [Keytruda: what’s the true cost of the world’s bestselling cancer drug?](https://www.thebureauinvestigates.com/stories/2026-04-13/keytruda-whats-the-true-cost-of-the-worlds-bestselling-cancer-drug). An investigation examines the NHS cost of MSD's Keytruda, arguing that confidential pricing and dosing practices may lead to substantial overspending. It also reports on the drug's patent strategy and MSD's cancelled London R&D investment.
- 13 April 2026, icij.org: [How Merck turned its wonder drug into a blockbuster — and priced out cancer patients worldwide](https://www.icij.org/investigations/cancer-calculus/merck-keytruda-cancer-drug-price/). An ICIJ investigation reports that MSD, known as Merck in the US and Canada, has used extensive patenting and other practices to protect Keytruda revenues and pricing. It includes UK evidence alleging that the NHS overpays for the cancer medicine.

- [MSD deep dive](https://www.omniscan.ai/benchmarks/uk-pharma-2026-h1?entity=msd&view=deep-dive)
- [MSD PDF report](https://www.omniscan.ai/benchmarks/uk-pharma-2026-h1/reports/msd.pdf)

### Roche

**Roche moved among access, research, diagnostics and dealmaking**

Roche ranked 7th of 10 by average monthly share of coverage (2.9%) in the Pharma in the UK benchmark for H1 2026, with 101 mentions and a net tone of +14.

Its monthly rank moved from eighth in January to tenth in February, fifth in March and between sixth and ninth thereafter. January’s measured mix was led by M&A and licensing, while company-focused reporting covered NICE support for Gazyvaro, positive CT-388 obesity data and cervical-screening activity supported by Roche Diagnostics. March produced Roche’s highest share at 5.3%, with stories including a breast-cancer trial setback, its successful complaint against Bayer and an NHS sustainability scholarship. Access and diagnostics remained material in April and May through the Accu-Chek SmartGuide rollout, routine NHS access to Evrysdi and the CE Mark for the Elecsys Alzheimer’s blood test. June combined research and competitive pipeline reporting with ocrelizumab trial findings and the Axelios gene-sequencing launch. Visibility peaked in March 2026 at 5.3%, compared with 0.5% in February 2026. January 2026: NICE issued draft support for Roche’s Gazyvaro in lupus nephritis — pharmaphorum.com. April 2026: share fell 2.0 points to 3.3%, volume declined by seven to 21 and rank moved to eighth; stories included the Accu-Chek SmartGuide rollout and Roche’s chief executive warning about European pricing and regulation. March 2026: the UK PMCPA upheld Roche’s complaint concerning Bayer’s pre-authorisation promotion of Eylea HD — fiercepharma.com.

Key messages:

- Visibility peaked in March 2026 at 5.3%, compared with 0.5% in February 2026.
- January 2026: NICE issued draft support for Roche’s Gazyvaro in lupus nephritis — pharmaphorum.com.
- The UK PMCPA upheld Roche's complaint that Bayer's sponsorship of a meeting promoted Eylea HD before its UK authorisation. Bayer was found to have breached standards and discredited the pharmaceutical industry.
- Roche Diagnostics is sponsoring UK and Northern Ireland Insulin Safety Week 2026, focused on safer insulin use and diabetes technology. The article also notes NHS reimbursement for Roche's Accu-Chek SmartGuide CGM system.
- Roche has launched its Axelios gene-sequencing platform for academic and research facilities, including in the UK. The company aims to challenge Illumina in next-generation sequencing and build a major long-term franchise.
- NICE and NHS England have agreed routine access to SMA treatments, including Roche's risdiplam (Evrysdi), following a price agreement. The decision makes the treatment available long term to eligible NHS patients.

Leading themes:

- Clinical Trials & Research: 30.7% of Roche's coverage (theme index 3.11, net tone −10)
- M&A & Licensing: 17.8% of Roche's coverage (theme index 1.23, net tone 0)
- NHS Access & Pricing: 17.8% of Roche's coverage (theme index 1.4, net tone +22)

Notable positive coverage:

- 22 January 2026, pharmaphorum.com: [NICE backs Roche lupus drug that supports kidney function](https://pharmaphorum.com/news/nice-backs-roche-lupus-drug-supports-kidney-function). NICE has issued a draft recommendation supporting NHS use of Roche's Gazyvaro for adults with lupus nephritis in England and Wales. The decision could expand access to treatment for around 12,000 people.
- 13 March 2026, fiercepharma.com: [Bayer found to have discredited pharma industry after Roche row](https://www.fiercepharma.com/marketing/bayer-found-have-discredited-pharma-industry-after-bitter-roche-row). The UK PMCPA upheld Roche's complaint that Bayer's sponsorship of a meeting promoted Eylea HD before its UK authorisation. Bayer was found to have breached standards and discredited the pharmaceutical industry.
- 7 May 2026, diabetestimes.co.uk: [Roche Diagnostics supports Insulin Safety Week 2026 as part of commitment to diabetes care](https://diabetestimes.co.uk/roche-diagnostics-supports-insulin-safety-week-2026-as-part-of-commitment-to-diabetes-care/). Roche Diagnostics is sponsoring UK and Northern Ireland Insulin Safety Week 2026, focused on safer insulin use and diabetes technology. The article also notes NHS reimbursement for Roche's Accu-Chek SmartGuide CGM system.

Notable negative coverage:

- 9 March 2026, morningstar.com: [Dow Jones Top Company Headlines at 5 AM ET: Roche Breast-Cancer Treatment Falls Short of Primary Goal in Late-Stage Study | GSK ...](https://www.morningstar.com/news/dow-jones/202603091788/dow-jones-top-company-headlines-at-5-am-et-roche-breast-cancer-treatment-falls-short-of-primary-goal-in-late-stage-study-gsk). GSK agreed to sell rights to linerixibat to Alfasigma in a deal worth up to $690 million. Roche reported a late-stage breast-cancer trial setback involving giredestrant and Pfizer's Ibrance.
- 9 March 2026, morningstar.com: [Dow Jones Top Company Headlines at 7 AM ET: Hims & Hers Shares Double on Report of Wegovy Tie-Up | Roche ...](https://www.morningstar.com/news/dow-jones/202603093159/dow-jones-top-company-headlines-at-7-am-et-hims-hers-shares-double-on-report-of-wegovy-tie-up-roche). GSK licensed linerixibat to Alfasigma for up to $690 million. The briefing also reports a Roche breast-cancer trial setback involving Pfizer's Ibrance and a reported Wegovy platform tie-up.

- [Roche deep dive](https://www.omniscan.ai/benchmarks/uk-pharma-2026-h1?entity=roche&view=deep-dive)
- [Roche PDF report](https://www.omniscan.ai/benchmarks/uk-pharma-2026-h1/reports/roche.pdf)

### Sanofi

**Access breakthroughs punctuated Sanofi’s volatile competitive position**

Sanofi ranked 7th of 10 by average monthly share of coverage (2.9%) in the Pharma in the UK benchmark for H1 2026, with 106 mentions and a net tone of +2.

June was the strongest competitive month at sixth place and 3.3%, alongside extensive independent reporting on Tzield and Sarclisa. January 2026: NICE issued positive final draft guidance for Sanofi and Regeneron’s Dupixent in COPD, reported by PMLiVE. February 2026: share fell 0.8 percentage points to 2.3% while rank remained seventh; stories included the PMCPA ruling over Beyfortus claims and Sanofi’s investment in Altesa’s rhinovirus programme. May 2026: share fell 1.4 percentage points to 1.8% and rank moved from ninth to tenth; the captured stories were contextual mentions, including GSK Nucala coverage referring to Dupixent, rather than company-focused Sanofi developments. February 2026: Sanofi participated in Altesa BioSciences’ $75 million financing for a rhinovirus programme and Phase IIb COPD study, reported by Fierce Biotech. March 2026: Sanofi agreed to supply 600,000 Nuvaxovid doses for the UK spring vaccination programme, reported by Pharmacy in Focus. June 2026: NICE recommended Sanofi’s Tzield for eligible early-stage type 1 diabetes patients, reported by The Guardian. Sanofi's subcutaneous Sarclisa formulation has been approved in the UK, with the UK becoming the first market for its on-body injector version. The product is presented as offering more convenient multiple-myeloma treatment and potential NHS capacity benefits.

Key messages:

- January 2026: NICE issued positive final draft guidance for Sanofi and Regeneron’s Dupixent in COPD, reported by PMLiVE.
- NICE final draft guidance recommends Sanofi’s teplizumab for NHS reimbursement for eligible people with stage 2 type 1 diabetes. The article describes the treatment as the first UK licensed disease-modifying option to delay symptomatic disease.
- Sanofi participated in Altesa BioSciences' $75 million funding round for a rhinovirus antiviral programme. Altesa plans a Phase IIb COPD study enrolling patients in the UK and US.
- Sanofi's subcutaneous Sarclisa formulation has been approved in the UK, with the UK becoming the first market for its on-body injector version. The product is presented as offering more convenient multiple-myeloma treatment and potential NHS capacity benefits.
- UK travel-health authorities warned that Sanofi's Verorab rabies vaccine and another product are in short supply. Clinicians were advised to prioritise vaccination for travellers at highest risk.
- The UK pharmaceutical marketing watchdog PMCPA sanctioned Sanofi over its CEO’s claims comparing Beyfortus with Pfizer’s RSV vaccine Abrysvo. The ruling found the comments could undermine the UK vaccination programme and breached the industry code.

Leading themes:

- NHS Access & Pricing: 27.4% of Sanofi's coverage (theme index 2.2, net tone +52)
- Clinical Trials & Research: 22.6% of Sanofi's coverage (theme index 2.24, net tone −42)
- Financial Results & Pipeline: 11.3% of Sanofi's coverage (theme index 0.97, net tone −8)

Notable positive coverage:

- 27 January 2026, pmlive.com: [Sanofi and Regeneron's Dupixent receives positive NICE final draft guidance for COPD](https://pmlive.com/pharma_news/sanofi-and-regenerons-dupixent-receives-positive-nice-final-draft-guidance-for-copd/). NICE issued positive final draft guidance recommending Sanofi and Regeneron's Dupixent for NHS reimbursement for eligible adults with uncontrolled COPD. Sanofi UK said it would work to support implementation if final guidance is issued.
- 19 February 2026, fiercebiotech.com: [Sanofi backs Altesa's $75M series B to bankroll antiviral's midstage rhinovirus study](https://www.fiercebiotech.com/biotech/sanofi-backs-altesas-75m-series-b-bankroll-antivirals-mid-stage-rhinovirus-study). Sanofi participated in Altesa BioSciences' $75 million funding round for a rhinovirus antiviral programme. Altesa plans a Phase IIb COPD study enrolling patients in the UK and US.
- 18 June 2026, pharmaphorum.com: [UK will be first market for Sanofi's subcutaneous Sarclisa](https://pharmaphorum.com/news/uk-will-be-first-market-sanofis-subcutaneous-sarclisa). Sanofi's subcutaneous Sarclisa formulation has been approved in the UK, with the UK becoming the first market for its on-body injector version. The product is presented as offering more convenient multiple-myeloma treatment and potential NHS capacity benefits.

Notable negative coverage:

- 13 April 2026, mylondon.news: [Vaccine shortage 135 countries on Foreign Office high risk list](https://www.mylondon.news/lifestyle/travel/vaccine-shortage-uk-135-countries-33760493). UK health authorities warned of constrained supply of Sanofi's Verorab rabies vaccine and advised prioritising high-risk travellers. The article sets out rabies risks and travel advice.
- 13 April 2026, mirror.co.uk: [Foreign Office 135 countries 'high risk' as virus vaccinations low](https://www.mirror.co.uk/travel/foreign-office-135-countries-high-37004157). UK travel-health authorities warned that Sanofi's Verorab rabies vaccine and another product are in short supply. Clinicians were advised to prioritise vaccination for travellers at highest risk.
- 2 February 2026, bloomberg.com: [Sanofi Rebuked in UK Over RSV Claims Targeting Rival Pfizer Shot](https://www.bloomberg.com/news/articles/2026-02-02/sanofi-rebuked-in-uk-over-rsv-claims-targeting-rival-pfizer-shot). UK self-regulatory body PMCPA found Sanofi made misleading claims about Beyfortus and disparaged Pfizer's RSV vaccine. Sanofi accepted the findings and said it had strengthened internal compliance processes.

- [Sanofi deep dive](https://www.omniscan.ai/benchmarks/uk-pharma-2026-h1?entity=sanofi&view=deep-dive)
- [Sanofi PDF report](https://www.omniscan.ai/benchmarks/uk-pharma-2026-h1/reports/sanofi.pdf)

### Novartis

**M&A & Licensing shaped Novartis' media profile during H1 2026**

Novartis ranked 9th of 10 by average monthly share of coverage (2.5%) in the Pharma in the UK benchmark for H1 2026, with 89 mentions and a net tone of +24.

After February's decline, the company defended a hypertension-treatment patent against Teva, while March's recovery included contextual references to Novartis funding Scotland's SMA screening pilot. April company-focused stories paired the chief executive's call for a rethink of European drug pricing with the withdrawal of the EU Pluvicto label-expansion application. In May, Novartis set out NHS collaboration projects and supported cancer-patient information videos at the Beatson. June's lower share coincided with a company-focused examination of Pluvicto and emerging radiopharmaceutical research. January 2026: Novartis UK funded an advanced breast-cancer awareness campaign centred on patient experiences — Metro. February 2026: share fell from 3.2% to 1.5% and rank moved from sixth to ninth; Novartis contemporaneously defended a hypertension-treatment patent against Teva. April 2026: Novartis withdrew its EU Pluvicto label-expansion filing after regulatory concerns — Endpoints News. Scotland has begun a two-year newborn screening evaluation for spinal muscular atrophy, funded by the Scottish government and Novartis. The results will inform a UK National Screening Committee decision on permanent inclusion in newborn screening. Novartis UK backed calls for nationwide newborn screening for spinal muscular atrophy, arguing that earlier diagnosis would enable timely treatment. Its Zolgensma gene therapy has been available on the NHS since 2021.

Key messages:

- January 2026: Novartis UK funded an advanced breast-cancer awareness campaign centred on patient experiences — Metro.
- Scotland has begun a two-year newborn screening evaluation for spinal muscular atrophy, funded by the Scottish government and Novartis. The results will inform a UK National Screening Committee decision on permanent inclusion in newborn screening.
- Novartis UK backed calls for nationwide newborn screening for spinal muscular atrophy, arguing that earlier diagnosis would enable timely treatment. Its Zolgensma gene therapy has been available on the NHS since 2021.
- The article discusses UK prostate-cancer screening research and treatment developments, including NICE's recommendation of Pfizer's Talzenna. It focuses on Novartis' Pluvicto and emerging post-Pluvicto radiopharmaceutical research.
- Novartis Pharmaceuticals UK advocates NHS-industry collaborations as a way to improve services and patient outcomes. It highlights partnership projects with Gateshead Health Foundation Trust and The Royal Marsden.
- Novartis supported NHS Greater Glasgow and Clyde's new Beatson cancer-patient information videos through a collaborative working agreement. The videos aim to reduce anxiety and improve preparation for oncology appointments.

Leading themes:

- M&A & Licensing: 22.5% of Novartis's coverage (theme index 1.56, net tone +5)
- Clinical Trials & Research: 13.5% of Novartis's coverage (theme index 1.3, net tone +25)
- Financial Results & Pipeline: 13.5% of Novartis's coverage (theme index 1.16, net tone 0)

Notable positive coverage:

- 23 March 2026, dailymail.co.uk: [Scotland becomes first part of UK to screen babies for rare muscle...](https://www.dailymail.co.uk/wires/pa/article-15670073/Scotland-UK-screen-babies-rare-muscle-disease.html). A Scottish pilot will offer newborn screening for spinal muscular atrophy to enable earlier treatment. The programme is jointly funded by the Scottish Government and Novartis.
- 19 January 2026, mirror.co.uk: [Jesy Nelson meets Wes Streeting to demand no more babies are left paralysed by SMA](https://www.mirror.co.uk/news/health/jesy-nelson-meets-wes-streeting-36577488). Novartis UK backed calls for nationwide newborn screening for spinal muscular atrophy, arguing that earlier diagnosis would enable timely treatment. Its Zolgensma gene therapy has been available on the NHS since 2021.
- 10 June 2026, pharmaphorum.com: [After Pluvicto: Alpha radiopharma and prostate cancer](https://pharmaphorum.com/oncology/after-pluvicto-alpha-radiopharma-and-prostate-cancer). The article discusses UK prostate-cancer screening research and treatment developments, including NICE's recommendation of Pfizer's Talzenna. It focuses on Novartis' Pluvicto and emerging post-Pluvicto radiopharmaceutical research.

Notable negative coverage:

- 14 February 2026, thetimes.com: [NHS drug rules 'killing' UK life sciences, says pharma boss](https://www.thetimes.com/business/companies-markets/article/nhs-drug-rules-killing-uk-life-sciences-says-pharma-boss-hgkqssjkz). Novartis criticises NICE cost-effectiveness rules and says restricted NHS access has contributed to reduced UK investment and employment. The article covers the planned increase in NICE thresholds and broader concerns about UK life-sciences competitiveness.

- [Novartis deep dive](https://www.omniscan.ai/benchmarks/uk-pharma-2026-h1?entity=novartis&view=deep-dive)
- [Novartis PDF report](https://www.omniscan.ai/benchmarks/uk-pharma-2026-h1/reports/novartis.pdf)

### Moderna

**Moderna moved from tenth to fifth across an uneven period**

Moderna ranked 10th of 10 by average monthly share of coverage (2.3%) in the Pharma in the UK benchmark for H1 2026, with 80 mentions and a net tone of +63.

February’s rise to eighth coincided with MHRA authorisation of UK-manufactured Spikevax, an R&D reorganisation and the FDA’s refusal to review Moderna’s flu-vaccine filing. March fell to two measured items and tenth place; both were contextual rather than company-focused, including coverage of the UK pandemic-preparedness strategy. April moved to sixth as reporting concentrated on Moderna’s Phase 3 UK-US H5N1 bird-flu vaccine trial. May was also sixth, with coverage shifting to first-quarter results, international COVID-19 vaccine sales and the first UK government-partnership shipment. June ranked seventh as the Oxford collaboration on a preventative Lynch-syndrome cancer vaccine supplied the principal research story. Visibility peaked in April 2026 at 4.3%, compared with 0.4% in March 2026. January 2026: The Guardian reported on a successful Moderna- and Merck-financed Imperial College mRNA therapeutic-vaccine trial for melanoma. February 2026: The Independent reported MHRA approval of Moderna’s UK-manufactured Spikevax supply from Harwell for the NHS campaign. April 2026: Reuters reported that Moderna had started a late-stage UK-US trial of its experimental mRNA bird-flu vaccine. June 2026: The Independent reported the Moderna-Oxford trial of an mRNA vaccine intended to prevent cancers associated with Lynch syndrome. Moderna has begun a pivotal UK-US trial of its mRNA-1018 H5N1 bird flu vaccine, with around three-quarters of participants recruited in the UK. The article links the UK trial footprint to Moderna's UK vaccine facility and relationship with the country.

Key messages:

- Visibility peaked in April 2026 at 4.3%, compared with 0.4% in March 2026.
- January 2026: The Guardian reported on a successful Moderna- and Merck-financed Imperial College mRNA therapeutic-vaccine trial for melanoma.
- Moderna has begun a pivotal UK-US trial of its mRNA-1018 H5N1 bird flu vaccine, with around three-quarters of participants recruited in the UK. The article links the UK trial footprint to Moderna's UK vaccine facility and relationship with the country.
- Moderna reported first-quarter revenue above expectations, driven largely by international COVID-19 vaccine sales including an initial UK partnership shipment. It maintained its 2026 outlook despite a wider net loss linked to litigation costs.
- Moderna's first-quarter sales exceeded estimates, supported by overseas government supply agreements including its first UK shipment under a long-term deal. The company is seeking to diversify away from the US market.
- The MHRA authorised a UK phase 1/2 study of Moderna's investigational mRNA cancer-prevention vaccine for Lynch syndrome. The study is part of Moderna's wider UK partnership and clinical-research investment.

Leading themes:

- Clinical Trials & Research: 42.5% of Moderna's coverage (theme index 4.37, net tone +82)
- Vaccines & Public Health: 28.7% of Moderna's coverage (theme index 7.09, net tone +57)
- Financial Results & Pipeline: 16.3% of Moderna's coverage (theme index 1.4, net tone +15)

Notable positive coverage:

- 21 April 2026, reuters.com: [Moderna starts late-stage trial of bird flu vaccine in US, UK](https://www.reuters.com/legal/litigation/moderna-starts-late-stage-trial-bird-flu-vaccine-us-uk-2026-04-21/). Moderna has started a late-stage trial of its experimental mRNA bird-flu vaccine in the US and UK, involving around 4,000 healthy adults.
- 22 April 2026, pharmaphorum.com: [Pivotal trial of Moderna's H5N1 bird flu jab gets underway](https://pharmaphorum.com/news/pivotal-trial-modernas-h5n1-bird-flu-jab-gets-underway). Moderna has begun a pivotal UK-US trial of its mRNA-1018 H5N1 bird flu vaccine, with around three-quarters of participants recruited in the UK. The article links the UK trial footprint to Moderna's UK vaccine facility and relationship with the country.
- 1 May 2026, qz.com: [Moderna Q1 2026 earnings beat on international COVID vaccine sales](https://qz.com/moderna-q1-2026-earnings-revenue-international-covid-vaccine-050126). Moderna reported first-quarter revenue above expectations, driven largely by international COVID-19 vaccine sales including an initial UK partnership shipment. It maintained its 2026 outlook despite a wider net loss linked to litigation costs.

Notable negative coverage:

- 14 February 2026, endpoints.news: [Moderna vs FDA; Paul Hudson out at Sanofi; Why clinical trials are so costly; and more](https://endpoints.news/moderna-vs-fda-paul-hudson-out-at-sanofi-why-clinical-trials-are-so-costly-and-more/). A biopharma weekly roundup reports an FDA refusal-to-file for Moderna’s flu vaccine, Sanofi’s CEO change and pipeline setbacks, and AstraZeneca’s positive Phase 2 obesity-pill results. AstraZeneca plans to begin Phase 3 trials of elecoglipron this year.

- [Moderna deep dive](https://www.omniscan.ai/benchmarks/uk-pharma-2026-h1?entity=moderna&view=deep-dive)
- [Moderna PDF report](https://www.omniscan.ai/benchmarks/uk-pharma-2026-h1/reports/moderna.pdf)

## Methodology

- **Share of coverage**: an organisation's mentions divided by all mentions of the organisations tracked in the same sector that month, in UK earned media. It is the central measure of media visibility in Omniscan benchmarks. "Average monthly share" is the mean of the monthly shares across the reporting period.
- **Mention**: one article that covers an organisation, classified as positive, neutral or negative in tone. Articles are deduplicated, and an organisation's own websites and passing sponsorship name-checks are excluded, so only earned media counts.
- **Net tone**: positive mentions minus negative mentions, as a percentage of all mentions (range −100 to +100).
- **Themes**: every article is assigned to one of the sector's editorial themes. A theme index above 1 means the organisation is covered on that theme more than its peers are; below 1 means less.
- **Calculation**: every figure is computed directly from the classified articles; narrative summaries are checked against those figures.
- **Sources**: UK national and international, trade and specialist, regional and local, and aggregator and syndication earned media.

## Other Pharma in the UK editions

- [UK pharma media reputation tracker – 2026 year to date](https://www.omniscan.ai/benchmarks/uk-pharma-2026-ytd.md)
- [UK pharma media reputation tracker – July 2026](https://www.omniscan.ai/benchmarks/uk-pharma-2026-07.md)
- [UK pharma media reputation tracker – August 2026](https://www.omniscan.ai/benchmarks/uk-pharma-2026-08.md)
- [UK pharma media reputation tracker – September 2026](https://www.omniscan.ai/benchmarks/uk-pharma-2026-09.md)
- [UK pharma media reputation tracker – October 2026](https://www.omniscan.ai/benchmarks/uk-pharma-2026-10.md)
- [All Omniscan media benchmarks](https://www.omniscan.ai/benchmarks.md)

## How to cite

Omniscan, "UK pharma media reputation tracker", H1 2026 (1 January 2026–30 June 2026), published 1 September 2026. https://www.omniscan.ai/benchmarks/uk-pharma-2026-h1
